A Meta-analysis of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis

To assess the efficiency and safety of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). The electronic databases of PubMed, EMBASE, Cochrane Library, Web of Science, Chinese BioMedical Literature Database (CBM) and Wanfang Data were searched for all randomi...

Full description

Saved in:
Bibliographic Details
Published inChung-hua nei kʿo tsa chih Vol. 52; no. 10; p. 838
Main Authors Yang, Lin, Tian, Jin-hui, He, Zhi-yu, Tang, Xu-lei, Yang, Ke-hu
Format Journal Article
LanguageChinese
Published China 01.10.2013
Subjects
Alendronate - pharmacology
Alendronate - therapeutic use
Bone Density
Glucocorticoids - adverse effects
Humans
Osteoporosis - chemically induced
Osteoporosis - prevention & control
Randomized Controlled Trials as Topic
Online AccessGet more information

Cover

More Information
Summary:To assess the efficiency and safety of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). The electronic databases of PubMed, EMBASE, Cochrane Library, Web of Science, Chinese BioMedical Literature Database (CBM) and Wanfang Data were searched for all randomized controlled trials (RCT) of alendronate vs. placebo. Two reviewers independently selected trials for inclusion, assessed trial quality using Jadad's scale and extracted the data. RevMan 5.1 software was used for data synthesis and Meta-analysis. Seven studies with 1111 patients were included. Compared with placebo, alendronate significantly increased bone mineral density (BMD) at the lumbar spine[MD = 3.35, 95%CI (2.67-4.02), P = 0.000] and the femoral neck[MD = 1.90, 95%CI (0.89-2.92), P = 0.000] after 12 months of therapy. After 24 months of therapy, alendronate significantly increased BMD at the lumbar spine[MD = 3.91, 95%CI (2.37-5.45), P = 0.000], but not at the femoral neck[MD = 1.91, 95%CI (-1.15-5.02), P
ISSN:0578-1426